SHORT COMMUNICATIONSAberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapyMirzakhani, Hoomana,b,c,*; van Dormolen, Juliëtd,*; van der Weide, Karene; Guchelaar, Henk-Janc; van Noorden, Martijn S.d; Swen, JessecAuthor Information aDepartment of Medicine, Channing Division of Network Medicine, Brigham and Women’s Hospital bDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA cDepartment of Clinical Pharmacy & Toxicology dDepartment of Psychiatry, Leiden University Medical Center, Leiden University, Leiden, The Netherlands eDepartment of Clinical Chemistry, St Jansdal Hospital, Harderwijk, The Netherlands * Hooman Mirzakhani and Juliët van Dormolen contributed equally to the writing of this article. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pharmacogeneticsandgenomics.com). Correspondence to Jesse Swen, PharmD, PhD, Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden University, PO Box 960, NL 2300 RC Leiden, The Netherlands Tel: +31 (0)71 526 2790; fax: +31 (0)71 526 6980; e-mail: [email protected] Received January 19, 2015 Accepted July 8, 2015 Pharmacogenetics and Genomics: October 2015 - Volume 25 - Issue 10 - p 515-517 doi: 10.1097/FPC.0000000000000167 Buy SDC Metrics Abstract We investigated the accumulation of aberrant CYP2D6 genotypes and predicted metabolizer phenotypes (ultrarapid metabolizer, intermediate metabolizer and poor metabolizer) potentially affecting the antidepressant treatment response in depressive patients indicated for electroconvulsive therapy (ECT) compared with patients with a single episode of depression. Seventy-six Dutch White patients with unipolar or bipolar treatment-resistant depression who underwent ECT were genotyped using the Amplichip CYP450 Test for CYP2D6. Two hundred and eight patients with a single episode of unipolar or bipolar depression were used as controls. No difference was observed in the prevalence of CYP2D6 phenotypes (poor metabolizer, intermediate metabolizer, extensive metabolizer and ultrarapid metabolizer) between the ECT and the control patients (5.3, 38.7, 56.0 and 0.0% vs. 6.4, 51.0, 42.6 and 0.0%, respectively). The types of depression (odds ratio=0.33, P=0.018) and age (odds ratio=1.55 for a 10-year increase, P<0.001), but not CYP2D6 phenotype or activity score were associated with the response to antidepressant treatment. In conclusion, preemptive genotyping for CYP2D6 currently appears to have no clinical implications in treatment-resistant depressive patients indicated for ECT. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.